Double Bond Pharmaceutical International AB

Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.

Quotes for Double Bond Pharmaceutical International AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Igor Lokot

Chairperson of the Board

  • Sanna Rejnlander

Board

  • Igor Lokot
  • Irina Zaitseva
  • Sergey Yanitsky
  • Articles of association

    • News

    Show More

    News agencies

    Show More

    Analysis

    Videos

    Double Bond sitdown

    BeloGal® and SA-033 (svenska)

    BeloGal® and SA-033 (english)

    Aktiespararna intervjuar VD Igor Lokot

    Largest Owners

    Name Capital % Votes % Date
    Igor Lokot 9,01 16,06 2025-03-27
    KSDR Hamberg AB 7,82 7,21 2025-03-27
    Per Ahlström 7,74 7,14 2025-03-27
    Carl Carvalho 4,02 3,71 2025-03-27
    Nowo Fund Management AB 3,30 3,05 2025-05-31
    Investentia AB 3,19 2,95 2025-03-27
    Lars-Åke Börje Flarke 3,19 2,94 2025-03-27
    Avanza Pension 2,79 2,58 2025-03-27
    Magnus Hamberg 2,57 2,37 2025-03-27
    Thomas Trumstedt 2,15 1,98 2025-03-27
    ** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

    Insider trading

    *Source: Holdings by Modular Finance AB. Compiled and processed data from the Swedish Financial Supervisory Authority

    Key Numbers

    *Compiled data from Millistream

    Upcoming reports

    • 2025-08-26 Delårsrapport 2025-Q2

    • 2025-11-25 Delårsrapport 2025-Q3

    Annual reports, prospectus etc.